Hôpital Pitié Salpêtrière - AP-HP

98 currently recruiting clinical trials
Create patient profile for matching
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Artios Pharma Ltd
Phase 1 / Phase 2 Endometrial cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B3
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B1
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Artios Pharma Ltd
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B5
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Artios Pharma Ltd
Phase 1 / Phase 2 Pancreas cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B6
Required histologic sub types
Adenocarcinoma Other
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Artios Pharma Ltd
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B2
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Artios Pharma Ltd
Phase 1 Lymphoma #NCT07308132
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Janssen
Phase 1 Lung cancer #NCT06026410
Bras 7 (CBNPC KRAS G12C)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Kura Oncologie, Inc.
Phase 1 Lung cancer Colon cancer Rectal cancer Pancreas cancer #NCT06026410
Bras 3 (NSCLC/CRC/PDAC KRAS G12C muté)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Kura Oncologie, Inc.
Phase 1 Kidney cancer #NCT06026410
Bras 4, 5 et 6 Carcinome rénal à cellules claires (CRCC)
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Kura Oncologie, Inc.